We examined the effect of the PTPN2 inhibitors on the IFNγ signaling response of mouse melanoma and colon cancer cell lines in vitro by comparing the effectiveness of the PTPN2 inhibitors with results of CRISPR/Cas9-mediated Ptpn2 deletion. The gene discussed is PTPN2; the disease is colonic neoplasm.